Compare BIO & UMBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIO | UMBF |
|---|---|---|
| Founded | 1952 | 1913 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Major Banks |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 8.2B |
| IPO Year | N/A | N/A |
| Metric | BIO | UMBF |
|---|---|---|
| Price | $304.33 | $118.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $358.50 | $136.27 |
| AVG Volume (30 Days) | 158.4K | ★ 436.7K |
| Earning Date | 10-29-2025 | 01-27-2026 |
| Dividend Yield | N/A | ★ 1.46% |
| EPS Growth | N/A | ★ 10.98 |
| EPS | N/A | ★ 8.89 |
| Revenue | ★ $2,557,500,000.00 | $2,217,071,000.00 |
| Revenue This Year | $1.77 | $69.52 |
| Revenue Next Year | $2.30 | $7.83 |
| P/E Ratio | ★ N/A | $13.29 |
| Revenue Growth | N/A | ★ 45.52 |
| 52 Week Low | $211.43 | $82.00 |
| 52 Week High | $373.69 | $126.14 |
| Indicator | BIO | UMBF |
|---|---|---|
| Relative Strength Index (RSI) | 42.52 | 63.52 |
| Support Level | $307.08 | $117.05 |
| Resistance Level | $319.50 | $120.58 |
| Average True Range (ATR) | 8.41 | 2.93 |
| MACD | -1.74 | 0.88 |
| Stochastic Oscillator | 10.83 | 79.95 |
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking services and asset servicing to its customers in the United States and around the world. Its client base includes commercial, institutional, and personal customers. Along with its subsidiaries, the company operates in the following business segments: Commercial Banking, Institutional Banking, and Personal Banking. A majority of its revenue is generated from the Commercial Banking segment, which serves the commercial banking and treasury management needs of small to middle-market businesses through various products and services such as commercial loans, commercial real estate financing, commercial credit cards, letters of credit, loan syndication services, consultative services, and others.